ArticleACS biomaterials science & engineering2019
Model Particulate Drug Carriers Modulate Leukocyte Adhesion in Human Blood Flows.
Article in ACS biomaterials science & engineering, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Harnessing Targeted Polymerized Salicylic Acid Particles to Mitigate Neutrophil-Driven Inflammation.ACS biomaterials science & engineering · 2026Article
- Development of DNase-1 Loaded Polymeric Nanoparticles Synthesized by Inverse Flash Nanoprecipitation for Neutrophil-Mediated Drug Delivery to In Vitro Thrombi.Advanced healthcare materials · 2025Article
- Rod-shaped Polymerized Salicylic Acid Particles Modulate Neutrophil Transendothelial Migration in Acute Inflammation.Advanced healthcare materials · 2025Article
- Cargo-free particles divert neutrophil-platelet aggregates to reduce thromboinflammation.Nature communications · 2023Article
- Nanoparticles reduce monocytes within the lungs to improve outcomes after influenza virus infection in aged mice.JCI insight · 2022Article
- Article
- Polysalicylic Acid Polymer Microparticle Decoys Therapeutically Treat Acute Respiratory Distress Syndrome.Advanced healthcare materials · 2022Article
- A whole-body circulatory neutrophil model with application to predicting clinical neutropenia from in vitro studies.CPT: pharmacometrics & systems pharmacology · 2021Article
- Neutrophil Inflammatory Response Is Downregulated by Uptake of Superparamagnetic Iron Oxide Nanoparticle Therapeutics.Frontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Drug carriers have been widely explored as a method of improving the efficacy of therapeutic drugs for a variety of diseases, including those involving inflammation. However, few of these formulations have advanced past clinical trials. There are still major gaps in our understanding of how drug carriers impact leukocytes, particularly in inflammatory conditions. In this work, we investigated how targeted and nontargeted drug carriers affect the function of leukocytes in blood flow. We explored three primary mechanisms: (1) collisions in blood flow disrupt leukocyte adhesion, (2) specific binding to the endothelium competes with leukocytes for binding sites, and (3) particle phagocytosis alters leukocyte phenotype, resulting in reduced adhesion. We find that each of these mechanisms contributes to significantly reduced leukocyte adhesion to an inflamed endothelium, and that particle phagocytosis may be the most significant driver of this effect. These results are crucial for understanding the totality of the impact of drug carriers on leukocyte behavior and response to inflammation and should inform the future design of any such drug carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.